ACP
ATRS

Acuta Capital Partners’s Antares Pharma, Inc. ATRS Stock Holding History

Acuta Capital Partners’s Portfolio ATRS Stock Details ATRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-232,762
Closed -$598K – 67
2014
Q4 		$598K Buy
+232,762
New +$523K 0.4% 51

Other funds holding ATRS

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WHI
William Harris Investors Chicago, Illinois $347M AUM 3.53% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Acuta Capital Partners's ATRS Position: Q1 2015 in Review

Acuta Capital Partners sold out of Antares Pharma, Inc. (ATRS) in Q1 2015, closing a stake of 232,762 shares — an estimated $598K sold.

Acuta Capital Partners first reported a position in ATRS in Q4 2014 and held it in 1 quarter. The position peaked at $598K in Q4 2014. 81 funds tracked by Wall St. Rank hold ATRS as of Q1 2015.

  • Acuta Capital Partners reported no remaining Antares Pharma, Inc. position as of Q1 2015 after selling out during the quarter.
  • Acuta Capital Partners sold 232,762 Antares Pharma, Inc. shares in Q1 2015, an estimated $598K.
  • Acuta Capital Partners first reported a position in Antares Pharma, Inc. in Q4 2014 and held it in 1 quarter.
  • Acuta Capital Partners's Antares Pharma, Inc. position peaked at $598K in Q4 2014.
  • 81 funds tracked by Wall St. Rank held Antares Pharma, Inc. as of Q1 2015.

Based on Acuta Capital Partners's 13F filing for Q1 2015, filed 15 May 2015.